LT3551619T - Kompozicijos, apimančios metilfenidato provaistus, jų gamybos ir panaudojimo būdai - Google Patents
Kompozicijos, apimančios metilfenidato provaistus, jų gamybos ir panaudojimo būdaiInfo
- Publication number
- LT3551619T LT3551619T LTEPPCT/US2017/065482T LTUS2017065482T LT3551619T LT 3551619 T LT3551619 T LT 3551619T LT US2017065482 T LTUS2017065482 T LT US2017065482T LT 3551619 T LT3551619 T LT 3551619T
- Authority
- LT
- Lithuania
- Prior art keywords
- promotions
- manufacture
- methods
- compositions containing
- containing methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662432675P | 2016-12-11 | 2016-12-11 | |
| US201762519627P | 2017-06-14 | 2017-06-14 | |
| US201762541695P | 2017-08-05 | 2017-08-05 | |
| PCT/US2017/065482 WO2018107132A1 (en) | 2016-12-11 | 2017-12-09 | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3551619T true LT3551619T (lt) | 2024-06-25 |
Family
ID=62491385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2017/065482T LT3551619T (lt) | 2016-12-11 | 2017-12-09 | Kompozicijos, apimančios metilfenidato provaistus, jų gamybos ir panaudojimo būdai |
Country Status (24)
| Country | Link |
|---|---|
| US (10) | US10584113B2 (lt) |
| EP (2) | EP3551619B1 (lt) |
| JP (1) | JP6963614B2 (lt) |
| KR (1) | KR102337138B1 (lt) |
| CN (1) | CN110234636B (lt) |
| AU (2) | AU2017371327B2 (lt) |
| BR (1) | BR112019011640B1 (lt) |
| CA (1) | CA3046486A1 (lt) |
| DK (1) | DK3551619T3 (lt) |
| ES (1) | ES2979262T3 (lt) |
| FI (1) | FI3551619T3 (lt) |
| HR (1) | HRP20240748T1 (lt) |
| HU (1) | HUE067004T2 (lt) |
| IL (3) | IL322584A (lt) |
| LT (1) | LT3551619T (lt) |
| MX (1) | MX390156B (lt) |
| NZ (1) | NZ754751A (lt) |
| PL (1) | PL3551619T3 (lt) |
| PT (1) | PT3551619T (lt) |
| RS (1) | RS65591B1 (lt) |
| SI (1) | SI3551619T1 (lt) |
| SM (1) | SMT202400217T1 (lt) |
| WO (1) | WO2018107132A1 (lt) |
| ZA (1) | ZA201903928B (lt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9653940B2 (en) | 2015-06-02 | 2017-05-16 | Voyetra Turtle Beach, Inc. | Headset wireless charging dock |
| HUE067004T2 (hu) | 2016-12-11 | 2024-10-28 | Zevra Therapeutics Inc | Metilfenidát prodrogokat tartalmazó készítmények, eljárások azok elõállítására és felhasználására |
| WO2019241020A1 (en) * | 2018-06-15 | 2019-12-19 | Kempharm, Inc. | Serdexmethylphenidate conjugates, compositions and methods of use thereof |
| US11136295B2 (en) | 2018-10-29 | 2021-10-05 | Kempharm, Inc. | D-amphetamine compounds, compositions, and processes for making and using the same |
| BR112022017133A2 (pt) * | 2020-02-29 | 2022-10-11 | Kempharm Inc | Composições compreendendo pró-drogas de metilfenidato, processos de fabricação e uso das mesmas |
| US11805352B2 (en) | 2021-05-28 | 2023-10-31 | Plantronics, Inc. | Wireless charging dock |
| US20250375436A1 (en) | 2024-03-25 | 2025-12-11 | Zevra Therapeutics, Inc. | Serdexmethylphenidate for treatment of idiopathic hypersomnia |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US5908850A (en) * | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
| US6622036B1 (en) | 2000-02-09 | 2003-09-16 | Cns Response | Method for classifying and treating physiologic brain imbalances using quantitative EEG |
| US6210705B1 (en) | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| AU2114199A (en) | 1998-01-13 | 1999-08-02 | Trustees Of The University Of Pennsylvania, The | Novel dopamine re-uptake inhibitors and methods of synthesizing and using the same |
| US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US20020132793A1 (en) | 2000-08-28 | 2002-09-19 | Mel Epstein | Use of methylphenidate compounds to enhance memory |
| JP2004507503A (ja) | 2000-08-28 | 2004-03-11 | センション,インコーポレイテッド | 記憶を増強するためのトレオ−メチルフェニデートの使用 |
| US7700561B2 (en) | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| IL151251A0 (en) | 2002-08-14 | 2003-04-10 | Elta Systems Ltd | Parallel processing platform with synchronous system halt-resume |
| US7247730B2 (en) | 2003-03-07 | 2007-07-24 | Isp Investments Inc. | Process for the preparation of dexmethylphenidate hydrochloride |
| CN1816346B (zh) * | 2003-05-29 | 2013-04-17 | 希拉有限责任公司 | 耐滥用的苯异丙胺化合物 |
| EP1812390A2 (en) | 2004-10-22 | 2007-08-01 | Mark Froimowitz | Methylphenidate analogs and methods of use thereof |
| EP1928881A2 (en) | 2005-08-19 | 2008-06-11 | Pharmacofore, Inc. | Prodrugs of active agents |
| EP2053919B1 (en) * | 2006-08-23 | 2013-12-25 | The University Of Montana | Method of reducing neuronal cell damage |
| US7772222B2 (en) | 2007-02-08 | 2010-08-10 | Mickle Travis C | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same |
| CA2672138A1 (en) | 2006-12-11 | 2008-06-19 | Kempharm, Inc. | Non-standard amino acid conjugates of amphetamine and processes for making and using the same |
| CA2677241A1 (en) | 2007-02-02 | 2008-08-14 | Colucid Pharmaceuticals, Inc. | Compounds that inhibit cholinesterase |
| US20100145057A1 (en) | 2007-03-15 | 2010-06-10 | Sun Pharma Advanced Research Company Ltd. | Novel prodrugs |
| CN101679366B (zh) | 2007-05-23 | 2013-08-07 | 默沙东公司 | 吡啶基哌啶食欲素受体拮抗剂 |
| WO2009035473A2 (en) | 2007-09-13 | 2009-03-19 | Sanfilippo Louis C | Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders |
| CN107261148B (zh) * | 2011-07-28 | 2021-07-13 | 凯姆制药公司 | 哌甲酯前药、其制备和使用方法 |
| WO2013088255A1 (en) | 2011-12-15 | 2013-06-20 | Alkermes Pharma Ireland Limited | Prodrugs of secondary amine compounds |
| US9088326B2 (en) | 2012-07-18 | 2015-07-21 | Rf Micro Devices, Inc. | Front end radio architecture having a split band arrangement with co-banding |
| WO2018107131A1 (en) | 2016-12-11 | 2018-06-14 | Kempharm, Inc. | Methylphenidate-prodrugs, processes of making and using the same |
| HUE067004T2 (hu) * | 2016-12-11 | 2024-10-28 | Zevra Therapeutics Inc | Metilfenidát prodrogokat tartalmazó készítmények, eljárások azok elõállítására és felhasználására |
| WO2019241020A1 (en) * | 2018-06-15 | 2019-12-19 | Kempharm, Inc. | Serdexmethylphenidate conjugates, compositions and methods of use thereof |
-
2017
- 2017-12-09 HU HUE17879353A patent/HUE067004T2/hu unknown
- 2017-12-09 DK DK17879353.5T patent/DK3551619T3/da active
- 2017-12-09 FI FIEP17879353.5T patent/FI3551619T3/fi active
- 2017-12-09 CN CN201780078718.4A patent/CN110234636B/zh active Active
- 2017-12-09 ES ES17879353T patent/ES2979262T3/es active Active
- 2017-12-09 NZ NZ754751A patent/NZ754751A/en unknown
- 2017-12-09 CA CA3046486A patent/CA3046486A1/en active Pending
- 2017-12-09 MX MX2019006670A patent/MX390156B/es unknown
- 2017-12-09 RS RS20240637A patent/RS65591B1/sr unknown
- 2017-12-09 PL PL17879353.5T patent/PL3551619T3/pl unknown
- 2017-12-09 AU AU2017371327A patent/AU2017371327B2/en active Active
- 2017-12-09 EP EP17879353.5A patent/EP3551619B1/en active Active
- 2017-12-09 BR BR112019011640-0A patent/BR112019011640B1/pt active IP Right Grant
- 2017-12-09 JP JP2019530444A patent/JP6963614B2/ja active Active
- 2017-12-09 SM SM20240217T patent/SMT202400217T1/it unknown
- 2017-12-09 IL IL322584A patent/IL322584A/en unknown
- 2017-12-09 PT PT178793535T patent/PT3551619T/pt unknown
- 2017-12-09 WO PCT/US2017/065482 patent/WO2018107132A1/en not_active Ceased
- 2017-12-09 HR HRP20240748TT patent/HRP20240748T1/hr unknown
- 2017-12-09 LT LTEPPCT/US2017/065482T patent/LT3551619T/lt unknown
- 2017-12-09 EP EP24161243.1A patent/EP4364802A3/en active Pending
- 2017-12-09 KR KR1020197017411A patent/KR102337138B1/ko active Active
- 2017-12-09 SI SI201731522T patent/SI3551619T1/sl unknown
-
2019
- 2019-06-04 US US16/431,422 patent/US10584113B2/en active Active
- 2019-06-04 US US16/431,275 patent/US10584112B2/en active Active
- 2019-06-04 US US16/431,468 patent/US10759778B2/en active Active
- 2019-06-06 IL IL267172A patent/IL267172A/en unknown
- 2019-06-18 ZA ZA2019/03928A patent/ZA201903928B/en unknown
- 2019-09-20 US US16/577,946 patent/US11021460B2/en active Active
- 2019-09-20 US US16/577,876 patent/US11021459B2/en active Active
- 2019-09-30 US US16/588,914 patent/US10954212B2/en active Active
-
2020
- 2020-02-18 US US16/794,170 patent/US10954213B2/en active Active
- 2020-02-18 US US16/793,923 patent/US10858341B2/en active Active
- 2020-09-24 AU AU2020239746A patent/AU2020239746B2/en active Active
- 2020-12-08 US US17/115,425 patent/US11505537B2/en active Active
-
2021
- 2021-04-26 US US17/240,181 patent/US20210253552A1/en not_active Abandoned
-
2022
- 2022-10-25 IL IL297652A patent/IL297652B2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50205A (fr) | Formulation de nicotine | |
| LT3775092T (lt) | Stabilizuotos fluorolefino kompozicijos ir jų gavimo, laikymo ir panaudojimo būdai | |
| EP3600325A4 (en) | UNIQUE COMPOSITIONS AND PROCESSES | |
| LT3443009T (lt) | Anti-tim-3 antikūnai ir kompozicijos | |
| LT3496739T (lt) | Kompozicijos ir būdai, skirti plaučių hipertenzijai gydyti | |
| LT3429596T (lt) | Cikliniai dinukleotidų junginiai ir panaudojimo būdai | |
| EP3436083A4 (en) | NOVEL COMPOSITIONS AND METHOD | |
| EP3509581A4 (en) | FORMULATIONS OF (R | |
| DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
| MA45188A (fr) | Oligonucléotides, compositions et méthodes associées | |
| LT3370770T (lt) | Anti-cd38 antikūnų poodinės kompozicijos ir jų panaudojimas | |
| LT3206497T (lt) | Kompozicijos ir būdai, skirti meibomo liaukos disfunkcijos gydymui | |
| LT3653221T (lt) | Anti-pvrig antikūnai ir naudojimo būdai | |
| EP3423058A4 (en) | NICOTINE FORMULATION AND AEROSOLS | |
| LT3551619T (lt) | Kompozicijos, apimančios metilfenidato provaistus, jų gamybos ir panaudojimo būdai | |
| PT3442586T (pt) | Formulação parentérica estável de nimodipina | |
| EP3599868C0 (en) | HERBICIDE MIXTURE, COMPOSITION AND PROCESS | |
| LT3490988T (lt) | Naujas junginys ir gavimo būdas | |
| LT3394259T (lt) | Tau raiškos mažinimo kompozicijos ir metodai | |
| LT3525583T (lt) | Anti-c1s antikūnai ir jų naudojimo būdai | |
| IL272851A (en) | Methods of using dipivefrin | |
| IL256322B (en) | Improved formulations of deferasirox and methods of making the same | |
| PL3319948T3 (pl) | Kompozycje acesulfamu potasowego i sposoby ich wytwarzania | |
| LT3128005T (lt) | Sirp-alfa varianto konstruktai, ir jų panaudojimas | |
| LT3399978T (lt) | Antiproliferaciniai junginiai, jų farmacinės kompozicijos ir naudojimas |